Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of di Novo Acute Myeloid Leukemia With the Combination of Increasing Doses of Idarubicin, Cytarabine and Sensitization (Priming) With G-CSF. A Phase II Prospective Study of Toxicity and Efficacy.

NCT01700413 is registered in ClinicalTrials.gov with Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias as lead sponsor.

NCT NCT01700413
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01700413 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of di Novo Acute Myeloid Leukemia With the Combination of Increasing Doses of Idarubicin, Cytarabine and Sensitization (Priming) With G-CSF. A Phase II Prospective Study of Toxicity and Efficacy.
Lead sponsor
Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2012
Completion date
April 30, 2015
Enrollment
48 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

di novo acute myeloid leukemia